Videos

Discover the critical timing and stability considerations for rectal spacers in radiation therapy, ensuring optimal patient outcomes and treatment precision.

Healthcare professionals discuss the importance of patient counseling on treatment options, emphasizing the balance between efficacy and quality of life.

Dean Elterman, MD, MSc, FRCSC, emphasizes that a key differentiator of this new class of devices lies in material science and mechanism of action.

Explore advancements in prostate cancer treatment, focusing on the role of rectal spacers in enhancing radiation therapy safety and effectiveness.

Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis.

Maxwell L. Sandberg, MD, highlights recent study findings on the role for perioperative systemic therapy for renal cell carcinoma with a tumor thrombus.

The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive implications for non–muscle invasive bladder cancer (NMIBC).

Mechanistically, Kaplan emphasizes that ProVee’s key differentiator is not simply that it is an expanding urethral device, but that it belongs to a new class of flexible, catheter-like technologies.

Raveen Syan, MD, FPMRS, shares her excitement about the Rising Star Program, now entering its second year.

The expert faculty explore how to select appropriate patients for future use of systemic immunotherapy combined with BCG in high-risk non–muscle invasive bladder cancer (NMIBC), assuming approval of durvalumab or sasanlimab.

Madison Krischak, MD, outlines key findings from a study looking at the use of nephrometry scores to guide routine renal mass biopsies.

Beyond the new features, attendees can expect a focused, high-yield scientific program covering both benign and oncologic disease.

The SOUL trial is exploring the feasibility of stent omission following uncomplicated ureteroscopy.

Overall, germline pathogenic variants were common, identified in approximately 1 in 7 tested patients.

Long-term data on sipuleucel-T reveals significant survival benefits, emphasizing the importance of multiple lines of therapy in patient outcomes.

Sameena A. Rahman, MD, said she sees this development as a hopeful signal amid a challenging landscape for women’s health care.

Experts discuss the importance of early treatment with Provenge for prostate cancer, highlighting patient demographics and response variability.

Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.

Daneshmand also emphasized the evolving, highly collaborative role between urologists and medical oncologists as perioperative systemic regimens expand.

Identifying the Ideal Patient for Doublet versus triplet in mCSPC

Discover how safe spacer placement enhances prostate cancer treatment, improves patient outcomes, and minimizes side effects during radiation therapy.

Mills warns that poorly justified combination regimens complicate downstream management for urologists.

Explore the latest long-term data on abiraterone and enzalutamide, revealing survival benefits and safety insights for prostate cancer treatments.

Discover how rectal spacers enhance prostate radiotherapy outcomes by reducing side effects and improving treatment precision in cancer care.

Laura Bukavina, MD, MPH, MSc, recapped a debate at SUO 2025 on how to appropriately classify high-grade bladder tumors.

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

Panelists discuss how closing real-world evidence gaps through inclusive research and advanced data integration will refine sequencing strategies and improve outcomes for patients with mCSPC.

The expert faculty review the phase 3 POTOMAC trial, presented at ESMO, which evaluated durvalumab combined with Bacillus Calmette–Guérin (BCG) in patients with high-risk, BCG-naïve non–muscle invasive bladder cancer (NMIBC).

Aleece Fosnight, MSPAS, PA-C, argues that incontinence must be understood as a common, treatable medical condition rather than a personal failure or an inevitable part of aging.

Panelists discuss how multidisciplinary collaboration and integration of RWE with NCCN guidelines strengthen ARPI adherence, sequencing, and continuity of care for patients with mCSPC.